As per the research report titled ‘Asia Pacific Monoclonal Antibodies Market Forecast 2027 By Type, By Application, By End-use, Research Report, Country Outlook, COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, available with MarketStudyReport, Asia Pacific monoclonal antibodies market which is estimated to amass valuation worth USD 80 million by 2027.

Escalating occurrence of chronic diseases such as cancer, increasing research & development in medical domain, and widespread acceptance the related therapies are all contributing to the growth of Asia Pacific monoclonal antibodies industry.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4129603/

Additionally, the market growth is propelled by the burgeoning biopharmaceutical sector, and the escalating utilization of monoclonal antibodies.

Looking at the downside, the high cost of a few monoclonal antibody (mAbs) therapies, and the strict regulation structure are restraining the industry share.

Speaking of type, the market classification comprises chimeric, fully human, humanized, and others. As per the report, the fully human monoclonal antibodies sector accounted for 51% industry share in the year 2020 and is expected to gain significant traction through 2027. The growth is attributed to the technological innovations, and the rising potential of phage display technologies for scalability, miniaturization, and parallelization.

As per application spectrum, Asia Pacific monoclonal antibodies market share is divided into infectious diseases, autoimmune diseases, oncology, and others. Among these, autoimmune disease application accounted for 31% market share in 2020 and is anticipated to grow over the forecasted duration, owing to the versatility of mAbs to modulate the immune system with high efficiency, thus preventing and treating autoimmune diseases.

Based on the end-user, the market is bifurcated into clinics, hospitals, and others. The hospital segment is projected to generate a revenue share of USD 34 billion by 2027, due to better accessibility to innovative and advanced treatment modalities in hospitals. In addition to that, the rising patient trust in advanced therapy and skilled professionals result in massive hospital admissions, adding to segmental share.

Witnessing the regional outlook, India is expected to be a sustainable economic hub for APAC mAbs market, with a 17.5 % annual growth rate through 2027. It is attributable to the rising incidence of chronic illnesses and susceptibility to pathogenic infections, as well as the severe consequences of the COVID-19 pandemic in the country.

Moving on to the competitive landscape, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novartis International AG, Johnson & Johnson, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Bristol Myers Squibb, and AbbVie Inc. are the companies influencing Asia Pacific monoclonal antibodies market trends.